盐酸埃克替尼治疗EGFR突变阳性非小细胞肺癌脑转移的近期效果分析

目的 探究盐酸埃克替尼对表皮生长因子受体（EGFR）突变阳性非小细胞肺癌脑转移的近期效果。方法 选取于南阳市中心医院肿瘤医院收治的EGFR突变阳性非小细胞肺癌脑转移患者共60例，所有患者均接受盐酸埃克替尼片口服治疗，125 mg/次，3次/d。回顾性分析其近期效果。结果 患者中位无进展生存期为12.6个月（95% CI 11.85~14.42）。所有患者均接受疗效评估，其中部分缓解（PR）23例，稳定（SD）37例，EGFR突变非小细胞肺癌（NSCLC）脑转移患者的有效率（ORR）为38.33%，疾病控制率（DCR）为100%。患者的治疗史、基因突变情况、性别以及吸烟与否与治疗无进展生存期（PFS）均无显著相关性（P>0.05）；患者的治疗史，性别与是否吸烟与ORR无显著相关性（P>0.05），而患者的基因突变情况与ORR显著相关（P<0.05）。不良反应发生情况：皮疹共出现5例，皮肤干燥9例，腹泻3例，肝功能异常2例。结论 盐酸埃克替尼治疗EGFR突变阳性非小细胞肺癌脑转移疗效显著，临床应用前景光明。

Short term effect of icotinib hydrochloride in treatment of EGFR mutation positive brain metastases from non-small cell lung cancer

Objective To explore the short-term effect of icotinib hydrochloride on EGFR mutation positive brain metastases from non-small cell lung cancer. Methods A total of 60 patients with brain metastasis from non-small cell lung cancer with EGFR mutation positive in Nanyang Central Hospital, Oncology Hospital were selected. All patients were treated with Icotinib Hydrochloride Tablets, 125 mg/time, orally, three times daily. Retrospective analysis of its short-term effect. Results The median PFS was 12.6 months (95%CI 11.85 to 14.42). All patients were evaluated for efficacy with 23 cases of PR and 37 cases of SD. The treatment of ORR in NSCLC were 38.33%, and DCR were 100%. There was no significant correlation between the history of treatment, gene mutation, sex and smoking history with PFS (P>0.05). There was no significant correlation between the history of treatment, sex, gender and whether smoking with ORR (P>0.05), and the gene mutation of patients was significantly correlated with ORR (P<0.05). Adverse reactions occurred in 5 cases of rash, 9 cases of skin drying, 3 cases of diarrhea, and 2 cases of abnormal liver function. Conclusion Icotinib hydrochloride treatment of EGFR mutation positive brain metastases of NSCLC has significant effect, with promising clinical application.